Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362476688> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4362476688 abstract "<div>Abstract<p>Mutations in fibroblast growth factor receptor 2 (<i>FGFR2</i>) have been recently described as a molecular-specific feature in endometrial carcinomas and the presence of activated <i>FGFR2</i> mutations is associated with poor prognosis. For that reason, inhibition of FGFR2 could be a therapeutic target in the treatment of endometriod carcinomas. In this work, we investigated the antitumoral activity of dovitinib (a multiple kinase inhibitor) in human endometrial cancer cell (ECC) lines. We found that dovitinib caused cell growth arrest, loss of clonogenic growth, and cell-cycle arrest in <i>FGFR2</i>-mutated ECCs in <i>in vitro</i> and <i>in vivo</i> experiments. Next, we investigated the mechanistic basis of dovitinib effects. We could determine that dovitinib modified expression levels of well-known key cell-cycle regulatory proteins that induce cellular senescence. To further investigate the role of dovitinib, we analyzed its effect on estrogen receptor α (ER-α) expression. Surprisingly, we discovered that dovitinib enhances ER-α expression in <i>FGFR2</i>-mutant ECCs. Because blocking one signaling pathway is often not sufficient to cause total tumor regression and the effectiveness of individual inhibitors is often short-lived, we examined the impact of targeting FGFR2 with dovitinib in combination with a selective ER antagonist, fulvestrant (ICI182.780). Combination of dovitinib plus ICI182.780 resulted in a significantly higher inhibition of cell growth than dovitinib treatment alone. These findings suggest that combinatory therapies using dovitinib plus ICI182.780 treatment can be truly effective in patients with endometrial carcinomas carrying FGFR2 mutations. <i>Mol Cancer Ther; 13(4); 776–87. ©2014 AACR</i>.</p></div>" @default.
- W4362476688 created "2023-04-05" @default.
- W4362476688 creator A5000012281 @default.
- W4362476688 creator A5010399021 @default.
- W4362476688 creator A5017346375 @default.
- W4362476688 creator A5032710158 @default.
- W4362476688 creator A5048002647 @default.
- W4362476688 creator A5049702399 @default.
- W4362476688 creator A5060906895 @default.
- W4362476688 creator A5069925431 @default.
- W4362476688 creator A5078445284 @default.
- W4362476688 date "2023-04-03" @default.
- W4362476688 modified "2023-10-18" @default.
- W4362476688 title "Data from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells" @default.
- W4362476688 doi "https://doi.org/10.1158/1535-7163.c.6536650.v1" @default.
- W4362476688 hasPublicationYear "2023" @default.
- W4362476688 type Work @default.
- W4362476688 citedByCount "0" @default.
- W4362476688 crossrefType "posted-content" @default.
- W4362476688 hasAuthorship W4362476688A5000012281 @default.
- W4362476688 hasAuthorship W4362476688A5010399021 @default.
- W4362476688 hasAuthorship W4362476688A5017346375 @default.
- W4362476688 hasAuthorship W4362476688A5032710158 @default.
- W4362476688 hasAuthorship W4362476688A5048002647 @default.
- W4362476688 hasAuthorship W4362476688A5049702399 @default.
- W4362476688 hasAuthorship W4362476688A5060906895 @default.
- W4362476688 hasAuthorship W4362476688A5069925431 @default.
- W4362476688 hasAuthorship W4362476688A5078445284 @default.
- W4362476688 hasConcept C117262875 @default.
- W4362476688 hasConcept C121608353 @default.
- W4362476688 hasConcept C126322002 @default.
- W4362476688 hasConcept C1491633281 @default.
- W4362476688 hasConcept C153911025 @default.
- W4362476688 hasConcept C185592680 @default.
- W4362476688 hasConcept C2780482068 @default.
- W4362476688 hasConcept C502942594 @default.
- W4362476688 hasConcept C530470458 @default.
- W4362476688 hasConcept C55493867 @default.
- W4362476688 hasConcept C62112901 @default.
- W4362476688 hasConcept C71924100 @default.
- W4362476688 hasConcept C84606932 @default.
- W4362476688 hasConcept C86803240 @default.
- W4362476688 hasConceptScore W4362476688C117262875 @default.
- W4362476688 hasConceptScore W4362476688C121608353 @default.
- W4362476688 hasConceptScore W4362476688C126322002 @default.
- W4362476688 hasConceptScore W4362476688C1491633281 @default.
- W4362476688 hasConceptScore W4362476688C153911025 @default.
- W4362476688 hasConceptScore W4362476688C185592680 @default.
- W4362476688 hasConceptScore W4362476688C2780482068 @default.
- W4362476688 hasConceptScore W4362476688C502942594 @default.
- W4362476688 hasConceptScore W4362476688C530470458 @default.
- W4362476688 hasConceptScore W4362476688C55493867 @default.
- W4362476688 hasConceptScore W4362476688C62112901 @default.
- W4362476688 hasConceptScore W4362476688C71924100 @default.
- W4362476688 hasConceptScore W4362476688C84606932 @default.
- W4362476688 hasConceptScore W4362476688C86803240 @default.
- W4362476688 hasLocation W43624766881 @default.
- W4362476688 hasOpenAccess W4362476688 @default.
- W4362476688 hasPrimaryLocation W43624766881 @default.
- W4362476688 hasRelatedWork W2060345758 @default.
- W4362476688 hasRelatedWork W2096086981 @default.
- W4362476688 hasRelatedWork W2107269111 @default.
- W4362476688 hasRelatedWork W2595652733 @default.
- W4362476688 hasRelatedWork W2619660538 @default.
- W4362476688 hasRelatedWork W2890928025 @default.
- W4362476688 hasRelatedWork W3117752638 @default.
- W4362476688 hasRelatedWork W4241300757 @default.
- W4362476688 hasRelatedWork W4361848299 @default.
- W4362476688 hasRelatedWork W4362283380 @default.
- W4362476688 isParatext "false" @default.
- W4362476688 isRetracted "false" @default.
- W4362476688 workType "article" @default.